Fundraising Fox
Aurinia Pharmaceuticals
Victoria, US · Founded 2009 · 3 known investors
Find your way into Aurinia Pharmaceuticals
Sign up to see every warm intro you have to Aurinia Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aurinia Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs. The company's marketed product LUPKYNIS treats active lupus nephritis, and it is also developing aritinercept for broader autoimmune indications.
Founders & leadership
Aurinia Pharmaceuticals was founded in 2009 by Richard M. Glickman.
Board
Investors · 3
How we know: Lumira Ventures's portfolio page · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$52M disclosed across 1 round · 2014
▶$52MraisedFeb 2014 · 22 investors · BiotechnologyRule 506(b)
- Kurt von EmsterDirector
- Benjamin RovinskiDirector
- Chris KimDirector
- Donald WyattDirector
- Stephen W. ZarubyExecutive Officer, Director
- Michael MartinExecutive Officer, Director
- Dennis BourgeaultExecutive Officer
- Daniel ParkDirector
- Richard M. GlickmanExecutive Officer, Director
- Peter WijngaardDirector
- Offering amount
- $52M
- Amount sold
- $52M
- Sales commissions
- $3.5M
- Placement agents
- Canaccord Genuity Inc., Leerink Partners LLC
- First sale
- Feb 2014
- Incorporated
- Corporation, Alberta, Canada, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Aurinia Pharmaceuticals do?
- Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs. The company's marketed product LUPKYNIS treats active lupus nephritis, and it is also developing aritinercept for broader autoimmune indications.
- Who founded Aurinia Pharmaceuticals?
- Aurinia Pharmaceuticals was founded by Richard M. Glickman in 2009.
- Who are Aurinia Pharmaceuticals's investors?
- Aurinia Pharmaceuticals's investors include Lumira Ventures, New Enterprise Associates (NEA), venBio Partners.
- How much funding has Aurinia Pharmaceuticals raised?
- Aurinia Pharmaceuticals has disclosed $52M raised across 1 round.
- Where is Aurinia Pharmaceuticals headquartered?
- Aurinia Pharmaceuticals is headquartered in Victoria, US.